Press Release: Humacyte Board of Directors Strengthened With Addition of John P. Bamforth and Keith Anthony Jones

Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage

Dow Jones53minutes ago

Humacyte Is Maintained at Buy by BTIG

Humacyte Is Maintained at Buy by

Dow Jones13:13 ET

Humacyte Price Target Raised to $11.00/Share From $8.00 by BTIG

Humacyte Price Target Raised to $11.00/Share From $8.00 by

Dow Jones13:13 ET

MicroStrategy, Coinbase, Robinhood, Tesla And Other Big Stocks Moving Higher On Monday

U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Monday.Shares of MicroStrategy Incorporated (NASDAQ:MSTR) rose sharply during Monday's session amid a rise Bitcoin.

BenzingaJul 15 11:04 ET

(HUMA) - Analyzing Humacyte's Short Interest

Humacyte's (NYSE:HUMA) short percent of float has risen 58.68% since its last report. The company recently reported that it has 8.25 million shares sold short, which is 9.14% of all regular shares

BenzingaJul 15 09:00 ET

BTIG Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $11

BTIG analyst Ryan Zimmerman maintains $Humacyte(HUMA.US)$ with a buy rating, and adjusts the target price from $8 to $11.According to TipRanks data, the analyst has a success rate of 47.8% and a

Moomoo NewsJul 15 08:31 ET · Ratings